Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia (DENWOLUTION)

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries. A promising strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy was implemented in Nouméa as part of the World Mosquito Program. This intervention will modify the epidemiological profile of arboviruses in New Caledonia.

Epidemiological surveillance of arboviruses requires molecular characterization of the virus contained in the serum obtained from the blood collected from patients. This molecular characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the construction of phylogenetic trees.

In the context of the implementation of the World Mosquito Program in Nouméa, the investigators plan to follow the molecular evolution of arboviruses, over the period preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a period of 5 years. following the releases.

At the same time, the virus can be isolated by cell culture techniques and in vitro infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.

Study Overview

• Status: Recruiting
• Conditions: Arbovirus Infections; Dengue; Chikungunya; Zika

Detailed Description

Collection of blood samples from patients with arbovirus infection

This study is a non-interventional study with retrospective part.

This study will improve :

• the assessment of the molecular evolution of arboviruses in the period preceding the implementation of the Wolbachia strategy
• the knowledge of the impact of Wolbachia on the diversity and molecular evolution of arboviruses
• the understanding of arbovirus transmission and replication mechanisms in the presence of Wolbachia

• Study Type: Observational
• Enrollment (Anticipated): 600

Contacts and Locations

• Study Contact: Name: Myrielle Dupont-Rouzeyrol, PhD; Phone Number: +687 27 75 30; Email: mdupont@pasteur.nc

Study Locations

• France
  • Nouvelle-Calédonie
    • Dumbéa Sur Mer, Nouvelle-Calédonie, France, 98 835
      • Recruiting
      • Centre Hospitalier Territorial
      • Contact: Ann-Claire Gourinat, MD; Phone Number: +687 208000; Email: ann-claire.gourinat@cht.nc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patient infected by arboviruses

Description

Inclusion Criteria:

• Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample,
• Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus.
• Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research,

Exclusion Criteria:

• Documented opposition from a patient or his representative (s)
• Previously established viral load too low.
• Sample obtained from a sample taken more than 7 days after the appearance of clinical signs of infection.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
arbovirus genome sequencing	Whole genome sequencing of virus extracted of blood samples from patients collected from 1995 to 2024	5 years
genetic evolution of arbovirus strains	bioinformatical analysis of the genome of the strains of arbovirus contained in serum samples collected from 1995 to 2024	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measurement of the impact of Wolbachia on the virus genetic evolution	comparison of viral genomes extracted from blood samples collected from 1995 to 2024	5 years
measurement of the ability of these viruses to replicate in the presence of Wolbachia	infection of cell lines with virus strains isolated and amplified from patient blood samples collected from 1995 to 2024	5 years

Collaborators and Investigators

• Sponsor: Institut Pasteur
• Collaborators: Institut Pasteur de Nouvelle-Calédonie; Centre Hospitalier Territorial de Nouvelle-Calédonie
• Investigators: Principal Investigator: Myrielle Dupont-Rouzeyrol, PhD, Institut Pasteur de Nouvelle-Calédonie

Publications and helpful links

General Publications

• Inizan C, Minier M, Prot M, O'Connor O, Forfait C, Laumond S, Marois I, Biron A, Gourinat AC, Goujart MA, Descloux E, Sakuntabhai A, Tarantola A, Simon-Loriere E, Dupont-Rouzeyrol M. Viral evolution sustains a dengue outbreak of enhanced severity. Emerg Microbes Infect. 2021 Dec;10(1):536-544. doi: 10.1080/22221751.2021.1899057.

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2020
• Primary Completion (Anticipated): July 17, 2025
• Study Completion (Anticipated): July 17, 2025

Study Registration Dates

• First Submitted: October 29, 2020
• First Submitted That Met QC Criteria: October 29, 2020
• First Posted (Actual): November 4, 2020

Study Record Updates

• Last Update Posted (Actual): October 7, 2022
• Last Update Submitted That Met QC Criteria: October 6, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: New Caledonia
• Additional Relevant MeSH Terms: Virus Diseases; Infections; Vector Borne Diseases; Arbovirus Infections
• Other Study ID Numbers: 2019-022

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No